Patient Inclusion Criteria

1. Subjects or their legal representatives have signed the informed consent form(ICF); agree not to participate in other clinical studies within 30 days after the last administration from the first administration of the study drug. 2. Subjects are aged ≥ 18 and ≤ 75; 3. Meet the diagnostic criteria for 2019-nCoV pneumonia (V5.0); 4. SOFA score: 1 ~ 13 points. 5. A retreated patient or the relapsed patient meets any of the following criteria: - Have fever again or aggravated clinical symptoms; ② 2019nCOVRNA in the throat swabs converts from negative to positive; ③ The clinical symptoms don't improve or 2019nCOVRNA continues to be positive; ④ The chest CT shows pneumonia or fibrosis progression. Clinical stratification: 1. Mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in CT, but positive 2019-nCoV in throat swabs or gargle. 2. Ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in CT. 3. Severe type: meeting any of the following criteria: (1) Respiratory distress, RR≥30 times/min; (2) Finger oxygen saturation ≤93% in rest state; (3) Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation (FiO2)≤300mmHg (1mmHg=0.133kPa). 4. Critical type: meeting any of the following criteria:(1)Respiratory failure occurs and mechanical ventilation is required;(2)Patients go into shock;(3)ICU is needed for other organ failure.

Patient Exclusion Criteria

1. Other viral pneumonia 2. Patients who have received tumor immunotherapy (such as PD-1/L1, CTLA4, etc.) in the past 1 month, and inflammatory factor modulators such as Ulinastatin; 3. Patients who have taken anti-bacterial drugs such as macrolide in the past 1 week; 4. Patients who have received organ transplantation or surgery planning in the past 6 months; 5. Patients who can't take food or drugs due to coma or intestinal obstruction; 6. Patients who have severe underlying diseases that affects survival, including uncontrolled malignant tumor with multiple metastases that cannot be resected, blood diseases, dyscrasia, active bleeding, severe malnutrition, etc. 7. Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation), or subjects that may fail to take effective contraceptive measures within the next 6 months; 8. Patients with allergic constitution, or patients allergic to macrolides and lopinavir/ritonavir tablets; 9. Patients with contraindications to lopinavir/ritonavir tablets who plan or are using drugs that interact with the drug (including: drugs that are highly dependent on CYP3A clearance and whose elevated plasma concentrations can be associated with severe and/or life-threatening events [with a narrow therapeutic index], CYP3A inducer [see instruction for details]) and cannot stop using or use other drugs instead; 10. Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal, or patients with child-Pugh grade C cirrhosis. 11. ECLS (ECMO, ECCO2R, RRT) 12. Critical patients with expected life 48 hours 13. Patients who have participated in any other clinical study within 1 month; 14. The investigators conclude that the patients not suitable for the study.